Role of vitronectin and its receptors in haemostasis and vascular remodeling

Thrombosis Research

Volumn 89, Issue 1, 1998, Pages 1-21

  Preissner, Klaus T ^a   Seiffert, Dietmar ^b  

^a KERCKHOFF HEART CENTER   (Germany)

^b DUPONT COMPANY   (United States)

Author keywords

Cell adhesion; Haemostasis; Integrins; Proteolytic enzyme cascades; Vascular remodeling; Vitronectin

Indexed keywords

APOLIPOPROTEIN E; GLYCOSAMINOGLYCAN; HEMOPEXIN; INTEGRIN; LIPOPROTEIN LIPASE; MATRIX METALLOPROTEINASE; OSTEOPONTIN; PLACENTA PROTEIN; SOMATOMEDIN B; TISSUE FACTOR PATHWAY INHIBITOR; VITRONECTIN RECEPTOR;

CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HEART VENTRICLE REMODELING; HEMOSTASIS; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

EID: 0031746579     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00298-3     Document Type: Article

References (169)

1. 1. Tomasini BR, Mosher DF. Vitronectin. Prog Hemostas Thromb 1990;10:269-305.
2. 2. Preissner KT. Structure and biological role of vitronectin. Ann Rev Cell Biol 1991;7:275-310.
3. 3. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 1995; 92:12426-30.
4. 4. Barnes DW, Silnutzer J. Isolation of human serum spreading factor. J Biol Chem 1983; 258:12548-52.
5. 5. Preissner KT, Wassmuth R, Müller-Berghaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 1985;231:349-55.
6. 6. Conlan MG, Tomasini BR, Schultz RL, Mosher DF. Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation. Blood 1988;72:185-90.
7. 7. Seiffert D, Geisterfer M, Gauldie J, Young E, Podor TJ. I1-6 stimulates vitronectin gene expression in vivo. J Immunol 1995;155: 3180-5.
8. 8. Parker CJ, Stone OL, White VF, Bernshaw NJ. Vitronectin (S-protein) is associated with platelets. Br J Haematol 1989;71:245-52.
9. 9. Preissner KT, Holzhüter S, Justus C, Müller-Berghaus G. Identification and partial characterization of platelet vitronectin: Evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989; 74:1989-96.
10. 10. Stockmann A, Hess S, Declerck P, Timpl R, Preissner KT. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 1993;268:22874-82.
11. 11. Hill SA, Shaughnessy SG, Joshua P, Ribau J, Austin RC, Podor TJ. Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. Blood 1996;87:5061-73.
12. 12. Seiffert D, Schleef RR. Two functionally distinct pools of vitronectin (VN) in the blood circulation: Identification of a heparin-binding competent population of VN within platelet α-granules. Blood 1996;88:552-60.
13. 13. Bronson RA, Preissner KT. Measurement of vitronectin content of human spermatozoa and vitronectin concentration within seminal fluid. Fertil Steril 1997;68:709-13.
14. 14. Pohl WR, Conlan MG, Thompson AB, Ertl RF, Romberger DJ, Mosher DF, Rennard SI. Vitronectin in bronchoalveolar lavage fluid is increased in patients with interstitial lung disease. Am Rev Respir Dis 1991;143: 1369-75.
15. 15. Jenne D, Stanley KK. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 1985;4:3153-7.
16. 16. Suzuki S, Oldberg A, Hayman EG, Pierschbacher MD, Ruoslahti E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J 1985;4:2519-24.
17. 17. Seiffert D, Keeton M, Eguchi Y, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991;88:9402-6.
18. 18. Seiffert D, Crain K, Wagner NV, Loskutoff DJ. Vitronectin gene expression in vivo -evidence for extrahepatic synthesis and acute phase regulation. J Biol Chem 1994;269: 19836-42.
19. 19. Seiffert D, Bordin GM, Loskutoff DJ. Evidence that extrahepatic cells express vitronectin in mRNA at rates approaching those of hepatocytes. Histochem Cell Biol 1996;105: 195-201.
20. 20. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ. Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol 1997;107:313-20.
21. 21. Seiffert D. Constitutive and regulated expression of vitronectin. Histol Histopathol 1997; 12:787-97.
22. 22. Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987;65:1-11.
23. 23. Guettier C, Hinglais N, Bruneval P, Kazatchkine M, Bariety J, Camilleri J-P. Immunohistochemical localization of S protein/ vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Arch A Pathol Anat 1989;414:309-13.
24. 24. Preissner KT, Pötzsch B. Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectin. Histol Histopathol 1995;10:239-51.
25. 25. Panetti TS, McKeown-Longo PJ. The αvβ5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993; 268:11492-5.
26. 26. Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, Preissner KT. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 1996;75:325-38.
27. 27. Tollefsen DM, Weigel CJ, Kabeer MH. The presence of methionine or threonine at position 381 in vironectin is correlated with proteolytic cleavage at arginine 379. J Biol Chem 1990;265:9778-81.
28. 28. Ogawa H, Yoneda A, Seno N, Hayashi M, Ishizuka I, Hase S, Matsumoto I. Structures of the N-linked oligosaccharides on human plasma vitronectin. Eur J Biochem 1995; 230:994-1000.
29. 29. Sato R, Komine Y, Imanaka T, Takano TJ. Monoclonal antibody EMR 1a/212D recognizing site of deposition of extracellular lipid in atherosclerosis. Isolation and characterization of a cDNA clone for the antigen. J Biol Chem 1990;265:21232-6.
30. 30. Ehrlich HJ, Richter B, von der Ahe D, Preissner KT. Primary structure of vitronectins and homology with other proteins. In: Preissner KT, Rosenblatt S, Wegerhoff J, Kost C, Mosher DF, editors. Biology of Vitronectins and Their Receptors. Amsterdam: Elsevier; 1993. p. 59-66.
31. 31. Otter M, Kuiper J, Rijken D, van Zonneveld A-J. Hepatocellular localisation of biosynthesis of vitronectin. Characterisation of the primary structure of rat vitronectin. Biochem Mol Biol Int 1995;37:563-72.
32. 32. Yoneda A, Kojima K, Matsumoto I, Yamamoto K, Ogawa H. Porcine vitronectin, the most compact form of single-chain vitronectin: The smallest molecular mass among vitronectins was ascribed to deletion and substitution of base pairs, and proteolytic trimming of the peptide. J Biochem 1996;120: 954-60.
33. 33. Blancher C, Omir B, Bidou L, Pessac B, Crisanti P. Nectinepsin - a new extracellular matrix protein of the pexin family. Characterization of a novel cDNA encoding a protein with an RGD cell binding motif. J Biol Chem 1996;271:26220-6.
34. 34. Nagano Y, Hamano T, Nakashima N, Ishikawa M, Miyazaki K, Hayashi M. Yolk vitronectin. Purification and differences from its blood homologue in molecular size, heparin binding, collagen binding, and bound carbohydrate. J Biol Chem 1992;267:24863-70.
35. 35. Bittorf SV, Williams EC, Mosher DF. Alteration of vitronectin. Characterization of changes induced by treatment with urea. J Biol Chem 1993;268:24838-46.
36. 36. Heldin C-H, Wasteson A, Fryklund L, Westermark B. Somatomedin B: Mitogenic activity derived from contaminant epidermal growth factor. Science 1981;213:1122-3.
37. 37. Ständker L, Enger A, Schulz-Knappe P, Wohn KD, Raida M, Germer M, Forssmann WG, Preissner KT. Structural and functional characterization of vitronectin-derived RGD-containing peptides from human hemofiltrate. Eur J Biochem 1996;241:557-63.
38. 38. Merberg DM, Fitz LJ, Temple P, Giannotti J, Murtha P, Fitzgerald M, et al. A comparison of vitronectin and megakaryocyte stimulating factor. In: Preissner KT, Rosenblatt S, Wegerhoff J, Kost C, Mosher DF, editors. Biology of Vitronectins and Their Receptors. Amsterdam: Elsevier; 1993. p. 45-53.
39. 39. Seiffert D, Loskutoff DJ. Evidence that type-1 plasminogen activator inhibitor binds to the somatomedin-B domain of vitronectin. J Biol Chem 1991;266:2824-30.
40. 40. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 1996;271:12716-23.
41. 41. Declerck PJ, De Mol M, Alessi M-C, Baudner S, Paques E-P, Preissner KT, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 988;263:15454-61.
42. 42. Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989;62:748-51.
43. 43. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolytic resistance. Studies with thrombi generated in the Chandler loop. Arterioscl Thromb 1994;14: 1452-8.
44. 44. Levi M, Biemond BJ, van Zonneveld A-J, Tencate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombin extension in models of experimental thrombosis. Circulation 1992; 85:305-12.
45. 45. Ehrlich HJ, Klein Gebbink R, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990;265:13029-35.
46. 46. Ehrlich HJ, Keijer J, Preissner KT, Klein Gebbink R, Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry 1991; 30:1021-8.
47. 47. Ehrlich HJ, Klein Gebbink R, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 1991;115:1773-81.
48. 48. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 1996;224:344-53.
49. 49. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-71.
50. 50. Jenne D, Hille A, Stanley KK, Huttner WB. Sulfation of two tyrosine-residues in human complement S-protein (vitronectin). Eur J Biochem 1989;185:391-5.
51. 51. Izumi M, Shimo-Oka T, Morishita N, Ii I, Hayashi M. Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Struct Funct 1988; 13:217-25.
52. 52. Cherny RC, Honan MA, Thiagarajan P. Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion. J Biol Chem 1993;268:9725-9.
53. 53. Tomasini-Johansson B, Ruoslahti E, Pierschbacher MD. A 30 kD sulfated extracellular matrix protein immunologically crossreactive with vitronectin. Matrix 1993;13:203-14.
54. 54. de Boer HC, Preissner KT, Bouma BN, de Groot PG. Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 1992;267: 2264-8.
55. 55. Jene D, Stanley KK. Nucleotide sequence and organization of the human S-protein gene: Repeating peptide motifs in the "pexin" family and a model for their evolution. Biochemistry 1987;26:6735-42.
56. 56. Liang OD, Rosenblatt S, Chhatwal GS, Preissner KT. Identification of novel heparin-binding domains of vitronectin. FEBS Lett 1997; 407:169-72.
57. 57. Liang OD, Preissner KT, Chhatwal GS. The hemopexin-type repeats of human vitronectin are recognized by Streptococcus pyogenes. Biochem Biophys Res Commun 1997;234: 445-9.
58. 58. Cardin AD, Weintraub HJR. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989;9:21-31.
59. 59. Chain D, Kreizman T, Shapira H, Shaltiel S. Plasmin cleavage of vitronectin: Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett 1991;285:251-6.
60. 60. Kost C, Stüber W, Ehrlich H, Pannekoek H, Preissner KT. Mapping of binding sites for heparin, plasminogen activator inhibitor-1 and plasminogen to vitronectin's heparin binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 1992; 267:12098-105.
61. 61. Rosenblatt S, Bassuk JA, Alpers CE, Sage EH, Timpl R, Preissner KT. Differential modulation of cell adhesion by interaction between adhesive and counteradhesive proteins: Characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochem J 1997;324:311-9.
62. 62. Gechtman Z, Belleli A, Lechpammer S, Shaltiel S. The cluster of basic amino acids in vitronectin contributed to its binding of plasminogen activator inhibitor-1: Evidence from thrombin-, elastase-and plasmin-cleaved vitronectins and anti-peptide antibodies. Biochem J 1997;325:339-49.
63. 63. Korc-Grodzicki B, Tauber-Finkelstein M, Chain D, Shaltiel S. Vitronectin is phosphorylated by a cAMP-dependent protein kinase released by activation of human platelets with thrombin. Biochem Biophys Res Commun 1988;157:1131-8.
64. 64. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type I promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100:58-67.
65. 65. Izumi M, Yamada KM, Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta 1989;990:101-8.
66. 66. Tomasini BR, Bosher DF, Owen MC, Fenton JW. Conformational lability of vitronectin: Induction of an antigenic change by α-thrombin-serpin complexes and by proteolytically modified thrombin. Biochemistry 1989;28: 832-42.
67. 67. Tomasini B, Mosher DF. Conformational states of vitronectin: Preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin III or treated with urea. Blood 1988;72:903-12.
68. 68. Seiffert D. Evidence that conformational changes upon the transition of the native to the modified form of vitronectin are not limited to the heparin binding domain. FEBS Lett 1995;368:155-9.
69. 69. Zhuang P, Li H, Williams JG, Wagner NV, Seiffert D, Peterson CB. Characterization of the denaturation and renaturation of human plasma vitronectin. 2. Investigation into the mechanism of formation of multimers. J Biol Chem 1996271:14333-43.
70. 70. Seiffert D. The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin. J Biol Chem 1997;272:9971-8.
71. 71. Zhuang P, Chen AI, Peterson CB. Native and mutimeric vitronectin exhibit similar affinity for heparin. J Biol Chem 1997;272;6858-67.
72. 72. Chain D, Korc-Grodzicki B, Kreizman T, Shaltiel S. The phosphorylation of the two-chain form of vitronectin by protein kinase A is heparin dependent. FEBS Lett 1990; 269:221-5.
73. 73. deBoer HC, de Groot PG, Bouma BN, Preissner KT. Ternary vitronectin-thrombin-antithrombin III complexes in human plasma: Detection and mode of association. J Biol Chem 1993;268:1279-83.
74. 74. Preissner KT, Müller-Berghaus G. Neutralisation and binding of heparin by S protein/ vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin binding domain of S protein/vitronectin. J Biol Chem 1987;262:12247-53.
75. 75. Hildebrand A, Preissner KT, Müller-Berghaus G, Teschemacher H. A novel β-endorphin binding protein. Complement S protein (=vitronectin) exhibits specific non-opioid binding sites for β-endorphin upon interaction with heparin or surfaces. J Biol Chem 1989;264:15429-34.
76. 76. Preissner KT, Grulich-Henn J, Ehrlich HJ, Declerck P, Justus C, Collen D, et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990;265:18490-8.
77. 77. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994;269: 14746-50.
78. 78. Seiffert D, Smith JW. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 1997;272:13705-10.
79. 79. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993;5:864-8.
80. 80. Vogel BE, Lee S-J, Hildebrand A, Craig W, Pierschbacher MD, Wong-Staal F, Ruoslahti E. A novel integrin specificity exemplified by biding of the αvβ5 integrin to the basic domain of the HIV tat protein and vitronectin. J Cell Biol 1993;121:461-8.
81. 81. Conforti G, Zanetti A, Pasuali-Ronchetti I, Quadlino D Jr, Neyroz P, Dejana E. Modulation of vitronectin receptor binding by membrane lipid composition. J Biol Chem 1990; 265:4011-9.
82. 82. D'Souza DE, Haas TA, Piotrowicz RS, Byers-Ward V, Mcgrath DE, Soule HR, et al. Ligand and cation binding are dual functions of a discrete segment of the integrin β3 subunit: Cation displacement is involved in ligand binding. Cell 1994;79:659-67.
83. 83. Loftus JC, Smith JW, Ginsberg MH. Integrin-mediated cell adhesion - the extracellular face. J Biol Chem 1994;269:25235-8.
84. 84. Orlando RA, Cheresh DA. Arginine-glycine-aspartic acid binding leading to molecular stabilization between integrin αvβ3 and its ligand. J Biol Chem 1991;266:19543-50.
85. 85. Conforti G, Calza M, Beltran-Nunez A. αvβ5 integrin is localized at focal contracts by HT-1080 fibrosarcoma cells and human skin fibroblasts attached to vitronectin. Cell Adhes Comm 1994;1:279-93.
86. 86. Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling required for integrin αvβ5-directed cell motility but not adhesion on vitronectin. J Cell Biol 1994;127:859-66.
87. 87. Yebra M, Parry GCN, Stomblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin αvβ5-directed cell migration. J Biol Chem 1996; 271:29393-9.
88. 88. Brown SL, Lundgren CH, Nordt G, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: Implications for atherosclerosis. Cardiovasc Res 1994;28:1815-20.
89. 89. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. Integrin β1-and β3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1992;121:163-70.
90. 90. Hendey B, Klee CB, Maxfield FR. Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. Science 1992;258: 296-9.
91. 91. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994;74:214-24.
92. 92. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. Adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of αvβ3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995;95:713-24.
93. 93. Bauer JS, Schreiner CL, Giancotti FG, Ruoslahti E, Juliano RL. Motility of fibronectin receptor-deficient cells on fibronectin and vitronectin. Collaborative interactions among integrins. J Cell Biol 1992;116:477-87.
94. 94. Blystone SD, Graham IL, Lindberg FP, Brown EJ. Integrin αvβ3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J Cell Biol 1994; 127:1129-37.
95. 95. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-61.
96. 96. Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 1994;127:537-46.
97. 97. Montgomery AMP, Reisfeld RA, Cheresh DA. Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994;91: 8856-60.
98. 98. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresh DA. Involvement of integrin αv gene expression in human melanoma tumorigenicity. J Clin Invest 1992;89:2018-22.
99. 99. Casaroli Marano RP, Preissner KT, Vilaro S. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 1995;60:5-17.
100. 100. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996;93:9764-9.
101. 101. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
102. 102. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
103. 103. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv-integrins. Science 1995;270:1500-2.
104. 104. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994;264:569-71.
105. 105. Gamble JR, Matthias IJ, Meyer G, Kaur P, Russ G, Faull R, et al. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 1993;121:931-43.
106. 106. Koolwijk P, van Erck MGM, de Vree WJA, Vermeer MA, Weich HA, Hanemaaijer R, van Hinsbergh VWM. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996;132: 1177-88.
107. 107. Mousa SA, Cheresh DA. Recent advances in cell adhesion molecules and extracellular matrix proteins: Potential clinical implications. Drug Dev Ther 1997;2:187-99.
108. 108. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Anti-integrin avβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
109. 109. Hammes HP, Brownlee M, Joncyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 1996;2:529-33.
110. 110. Choi Y, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994;19: 125-34.
111. 111. Savill J, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990; 343:180-3.
112. 112. Parker CJ, Frame RN, Elstad MR. Vitronectin (S protein) augments the functional activity of monocyte receptors for IgG and complement C3b. Blood 1988;71:86-93.
113. 113. Leven RM, Tablin F. Extracellular matrix stimulation of guinea pig megakaryocyte proplatelet formation in vitro is mediated through the vitronectin receptor. Exp Hematol 1992;20:1316-22.
114. 114. Coller BS, Seligsohn U, West SM, Scudder LE, Norton KJ. Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: Evidence consistent with specific roles for glycoprotein IIb/IIIa and αvβ3 integrins in platelet protein trafficking. Blood 1991;78: 2603-10.
115. 115. Zanetti A, Conforti G, Hess S, Martinpadura I, Ghibaudi E, Preissner KT, Dejana E. Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane. Blood 1995;84:1116-23.
116. 116. Lindberg FP, Gresham HD, Reinhold MI, Brown EJ. Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. J Cell Biol 1996; 134:1313-22.
117. 117. Bhattacharya S, Fu C, Bhattacharya J, Greenbert S. Soluble ligand of the αvβ3 integrin mediate enhanced tyrosine phosphorylation of multiple proteins in adherent bovine pulmonary artery endothelial cells. J Biol Chem 1995;28:16781-7.
118. 118. Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, Schomig A. Vitronectin receptor (αvβ3) mediates platelet adhesion to the luminal aspect of endothelial cells Implications for reperfusion in acute myocardial infarction. Circulation 1997;96: 1809-18.
119. 119. Murphy JF, Bordet JC, Wyler B, Rissoan MC, Chomarat P, Defrance T, et al. The vitronectin receptor (αvβ3) is implicated, in cooperation with P-selectin and platelet activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J 1994;304:537-42.
120. 120. Hess S, Kanse SM, Kost C, Preissner KT. The versatility of adhesion receptor ligands in haemostasis: Morpho-regulatory functions of vitronectin. Thromb Haemostas 1995;74: 258-65.
121. 121. Preissner KT, Anders E, Grulich-Henn J, Müller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S protein (vitronectin) as well as with the ternary S protein-thrombin-antithrombin III complex. Blood 1988;71: 1581-9.
122. 122. Preissner KT, de Boer H, Pannekoek H, de Groot PG. Thrombin regulation by physiological inhibitors: The role of vitronectin. Semin Thromb Haemostas 1996;22:165-72.
123. 123. Völker W, Hess S, Vischer P, Preissner KT. Binding and processing of multimeric vitronectin by vascular endothelial cells. J Histo Cytochem 1993;41:1823-32.
124. 124. Dahlbäck K, Löfberg H, Alumets J, Dahlbäck B. Immunohistochemical demonstration of age-related deposition of vitronectin (S-protein of complement) and terminal complement complex on dermal elastic fibers. J Invest Dermatol 1989;92:727-33.
125. 125. Senger DR. Molecular framework for angiogenesis. A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Path 1996;149:1-7.
126. 126. Preissner KT, May AE, Wohn KD, Germer M, Kanse SM. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling. Thromb Haemostas 1997;78:88-95.
127. 127. Chapman HA, Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-24.
128. 128. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269: 32380-8.
129. 129. Colman RW, Pixley RA, Najamunnisa S, Yan WY, Wang JY, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is medited via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997;100:1481-7.
130. 130. Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol 1992;116:465-76.
131. 131. Moser TL, Enghild JJ, Pizzo SV, Stack MS. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA dependent adhesion of U937 cells. Biochem J 1995;307:867-73.
132. 132. Higazi AA-R, Upson RH, Cohen RL, Manuppello J, Bognacki J, Henkin J, et al. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. Blood 1996;88: 542-51.
133. 133. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91:1-9.
134. 134. Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna F, Botti G, et al. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res 1997; 3:1299-1308.
135. 135. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscl Thromb Vasc Biol 1995;15: 1444-55.
136. 136. Ciambrone GJ, McKeown-Longo PJ. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 1992;267: 13617-22.
137. 137. Pöllänen J, Hedman K, Nielsen LS, Dano K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988;106:87-95.
138. 138. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-328.
139. 139. Kook YH, Adamski J, Zelent A, Ossowski L. the effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91.
140. 140. Gyetko MR, Todd RF III, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994;93:1380-7.
141. 141. Stefansson S, Lawrence DA, Argraves WS. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 1996; 271:8215-20.
142. 142. Dumler I, Petri T, Schleuning WD. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett 1994;343:103-6.
143. 143. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 1996; 383:441-3.
144. 144. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, et al. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232:420-9.
145. 145. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990;4:69-78.
146. 146. Reilly D, Christensen K, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Canc 1992;50:208-14.
147. 147. Carmeliet P, Collen D. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol 1997;8: 118-25.
148. 148. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
149. 149. Müller-Eberhard HJ. Molecular organization and function of the complement system. Ann Rev Biochem 1988;57:321-47.
150. 150. Preissner KT, de Groot PG. Platelet adhesion molecules in natural immunity. In: Sim E, Kerr MA, editors. The Natural Immune System: Humoral Factors. Oxford: Oxford University Press; 1993. p. 281-318.
151. 151. Tschopp J, Masson D, Schäfer S, Peitsch M, Preissner KT. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, C9 and perform from cytolytic T-cells and inhibits their lytic activities. Biochemistry 1988;27:4103-9.
152. 152. Basara ML, McCarthy JB, Barnes DW, Furcht LT. Stimulation of haptotaxis and migration of tumor cells by serum spreading factor. Cancer Res 1985;45:2487-94.
153. 153. Lim BL, Ried KBM, Ghebrehiwet B, Peerschke EIB, Lieght LAE, Pressner KT. The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor. J Biol Chem 1996;271:26739-44.
154. 154. Eggleton P, Ghebrehiwet B, Sastry KN, Coburn JP, Zaner KS, Reid KBM, Tauber AI. Identification of a gC1q-binding protein (gC1q-R) on the surface of human neutrophils. J Clin Invest 1995;95:1569-78.
155. 155. Fuquay JI, Loo DT, Barnes DW. Binding of Staphylococcus aureus by human serum spreading factor in an in vitro assay. Infect Immun 1986;52:714-7.
156. 156. Chhatwal GS, Preissner KT, Müller-Berghaus G, Blobel H. Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli. Infect Immun 1987;55:1878-83.
157. 157. Liang OD, Ascencio F, Fransson LA, Wadström T. Binding of heparan sulfate to staphylococcus aureus. Infect Immun 1992;60: 899-906.
158. 158. Liang OD, Maccarana M, Flock JI, Paulsson M, Preissner KT, Wadström T. Multiple interactions between human vitronectin and Staphylococcus aureus. Biochim Biophys Acta 1993;374:1-7.
159. 159. Valentin-Weigand P, Grulich-Henn J, Chhatwal GS, Müller-Berghaus G, Blobel H, Preissner KT. Mediation of adherence of streptococci to human endothelial cells by complement S-protein (vitronectin). Infect Immun 1988;56:2851-5.
160. 160. Duensing TD, van Putten JPM. Vitronectin mediates internalization of Neisseria gonorrheae by chinese hamster ovary cells. Infect immun 1997;65:964-70.
161. 161. Gomez Duarte OG, Dehio M, Guzman CA, Chhatwal GS, Dehio C, Meyer TF. Binding of vitronectin to OPA-expressing neisseria gonorrhoeae mediates invasion of hela cells. Infect Immun 1997;65:3857-66.
162. 162. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin αvβ5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994;127:257-64.
163. 163. Villaverde A, Feliu JX, Harbottle RP, Benito A, Coutelle C. A recombinant, arginine-glycine-aspartic acid (RGD) motif from foot-and-mouth disease virus binds mammalian cells through vitronectin and, to a lower extent, fibronectin receptors. Gene 1996;180: 101-6.
164. 164. Miyazaki K, Hamano T, Hayashi M. Physarum vitronectin-like protein - an Arg-Gly-Asp-dependent cell spreading protein with a distinct NH2-terminal sequence. Exp Cell Res 1992;199:106-10.
165. 165. Nakashima N, Miyazaki K, Ishikawa M, Yatohgo T, Ogawa H, Uchibori H, et al. Vitronectin diversity in evolution but uniformity in ligand-binding and size of the core polypeptide. Biochem Biophys Acta 1992;1120:1-10.
166. 166. Hynes RO, Bader BL. Targeted mutations in integrins and their ligands: Their implications for vascular biology. Thromb Haemostas 1992; 78:249-57.
167. 167. Fässler R, Georges-Labouesse E, Hirsch E. Genetic analysis of integrin function in mice. Curr Opin Cell Biol 1996;8:641-6.
168. 168. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin system: Implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 1995;9:934-8.
169. 169. Preissner KT, Chhatwal GS. Extracellular matrix (ECM) and host cell surfaces: Potential sites of pathogen interaction. In: Cossart P, Boquet P, Normark S, Rappuoli R, editors. Cellular Microbiology. Washington, DC: ASM Press; 1998.